LAGE3 promoted cell proliferation, migration, and invasion and inhibited cell apoptosis of hepatocellular carcinoma by facilitating the JNK and ERK signaling pathway

Springer Science and Business Media LLC - Tập 26 Số 1 - 2021
Ying Xing1, Yang Liu1, Qi Zhong1, Zhengrong Liu1, Xin Wang1, Hongyi Zhang1
1Department of General Surgery, Beijing Tiantan Hospital, Capital Medical University, No. 119, South 4th Ring West Road, Fengtai District, Beijing, 100070, China

Tóm tắt

Abstract Background Hepatocellular carcinoma (HCC) is now the second leading cause of cancer death worldwide and lacks effectual therapy due to its high rate of tumor recurrence and metastasis. The aim of this study was to investigate the effects of L antigen family member 3 (LAGE3, a member of the LAGE gene family involved in positive transcription) on the progression of HCC. Methods The expression of LAGE3 was detected by quantitative real-time polymerase chain reaction. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, colony formation assay, EdU, and cell cycle analysis assay were employed to evaluate the proliferation of HCC cells. Annexin V-FITC/PI and TUNEL assay were used to assess the apoptosis rate of HCC cells. Wound healing and transwell assay were used to investigate the migration and invasion of HCC cells. A xenograft model of HCC was established with 2 × 106 Hep3B or SK-HEP1 cells to investigate the in vivo effects of LAGE3. Then, the protein levels of LAGE3, p-p38, p-38, c-Jun N-terminal kinase (JNK),p-JNK, extracellular signal-regulated kinase (ERK), and p-ERK were detected by western blot. Results We found that LAGE3 was upregulated in HCC tissues compared to adjacent tissues, and its high expression was correlated with poor overall survival by bioinformatics analysis. Next, we manually regulated the expression of LAGE3 in HCC cells. The knockdown of LAGE3 inhibited the proliferation of HCC cells by arresting the cell cycle in G1 phase. Also the downregulation of LAGE3 inhibited cell migration and invasion and induced apoptosis of HCC cells, while overexpression of LAGE3 promoted the malignant phenotypes of HCC. These results were further confirmed by the in vivo growth of HCC xenografts and the inhibition of apoptosis of HCC tumor cells. Furthermore, we found that LAGE3 exerted cancer-promoting effects by potentiating the JNK and ERK signaling pathway. An ERK inhibitor (10 μM SCH772984) or JNK inhibitor (25 μM SP600125) repressed the upregulated LAGE3-induced proliferation, migration, and invasion of HCC cells. Conclusions LAGE3 enhanced the malignant phenotypes of HCC by promoting the JNK and ERK signaling pathway.

Từ khóa


Tài liệu tham khảo

Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589–604.

Ding H, Zhang X, Su Y, Jia C, Dai C. GNAS promotes inflammation-related hepatocellular carcinoma progression by promoting STAT3 activation. Cell Mol Biol Lett. 2020. https://doi.org/10.1186/s11658-020-00204-1.

Kong Q, Liang C, Jin Y, Pan Y, Tong D, Kong Q, et al. The lncRNA MIR4435–2HG is upregulated in hepatocellular carcinoma and promotes cancer cell proliferation by upregulating miRNA-487a. Cell Mol Biol Lett. 2019. https://doi.org/10.1186/s11658-019-0148-y.

Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology. 2019;156(2):477.

Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380(15):1450–62.

Torrecilla S, Sia D, Harrington AN, Zhang Z, Cabellos L, Cornella H, et al. Trunk mutational events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma. J Hepatol. 2017;67(6):1222–31.

Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–14.

Zhou C, Liu C, Liu W, Chen W, Yin Y, Li C-W, et al. SLFN11 inhibits hepatocellular carcinoma tumorigenesis and metastasis by targeting RPS4X via mTOR pathway. Theranostics. 2020;10(10):4627–43.

Alpen B, Güre AO, Scanlan MJ, Old LJ, Chen Y-T. A new member of the NY-ESO-1 gene family is ubiquitously expressed in somatic tissues and evolutionarily conserved. Gene. 2002;297(1–2):141–9.

Yan W, Chen J, Wei Z, Wang X, Zeng Z, Tembo D, et al. Effect of eleutheroside B1 on non-coding RNAs and protein profiles of influenza A virus-infected A549 cells. Int J Mol Med. 2020;45(3):753–68.

Beenstock J, Ona SM, Porat J, Orlicky S, Wan LCK, Ceccarelli DF, et al. A substrate binding model for the KEOPS tRNA modifying complex. Nat Commun. 2020;11(1):6233.

Braun DA, Rao J, Mollet G, Schapiro D, Daugeron M-C, Tan W, et al. Mutations in KEOPS-complex genes cause nephrotic syndrome with primary microcephaly. Nat Genet. 2017;49(10):1529–38.

Begik O, Lucas MC, Liu H, Ramirez JM, Mattick JS, Novoa EM. Integrative analyses of the RNA modification machinery reveal tissue- and cancer-specific signatures. Genome Biol. 2020;21(1):97.

Dong X, Yang Q, Gu J, Lv S, Song D, Chen D, et al. Identification and validation of L Antigen Family Member 3 as an immune-related biomarker associated with the progression of papillary thyroid cancer. Int Immunopharmacol. 2021;90:107267.

Dong X, Gu D-N, Wang O, Ye Z. LAGE3 correlates with tumorigenic immune infiltrates in the clear cell renal cell carcinoma microenvironment. Int Immunopharmacol. 2020;87:106793.

Zhou Y, Liang H, Deng J, Luo Z, Long W. LAGE3 is a potential therapeutic target and prognostic factor in breast cancer: database mining for LAGE family members in human malignancies, p. In (ed).

Dong X, Lv S, Gu D, Zhang X, Ye Z. Up-regulation of L antigen family member 3 associates with aggressive progression of breast cancer. Front Oncol. 2020;10:553628.

Spänkuch B, Matthess Y, Knecht R, Zimmer B, Kaufmann M, Strebhardt K. Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. J Natl Cancer Inst. 2004;96(11):862–72.

Khemlina G, Ikeda S, Kurzrock R. The biology of Hepatocellular carcinoma: implications for genomic and immune therapies. Mol Cancer. 2017;16(1):149.

Armengol C, Sarrias MR, Sala M. Hepatocellular carcinoma: present and future. Med Clin (Barc). 2018;150(10):390–7.

Thiaville PC, El Yacoubi B, Köhrer C, Thiaville JJ, Deutsch C, Iwata-Reuyl D, et al. Essentiality of threonylcarbamoyladenosine (t(6)A), a universal tRNA modification, in bacteria. Mol Microbiol. 2015;98(6):1199–221.

Wan LCK, Pillon MC, Thevakumaran N, Sun Y, Chakrabartty A, Guarné A, et al. Structural and functional characterization of KEOPS dimerization by Pcc1 and its role in t6A biosynthesis. Nucleic Acids Res. 2016;44(14):6971–80.

Song J, Jin C, Chen E, Dong X, Zhu L. L antigen family member 3 serves as a prognostic biomarker for the clinical outcome and immune infiltration in skin cutaneous melanoma. Biomed Res Int. 2021;201:6648182.

Khoa Ta HD, Tang W-C, Phan NN, Anuraga G, Hou S-Y, Chiao C-C, et al. Analysis of LAGEs family gene signature and prognostic relevance in breast cancer. Diagnostics (Basel). 2021;11(4):726.

Goswami MT, VanDenBerg KR, Han S, Wang LL, Singh B, Weiss T, et al. Identification of TP53RK-binding protein (TPRKB) Dependency in -deficient cancers. Mol Cancer Res. 2019;17(8):1652–64.

Guo Y-J, Pan W-W, Liu S-B, Shen Z-F, Xu Y, Hu L-L. ERK/MAPK signalling pathway and tumorigenesis. Exp Ther Med. 2020;19(3):1997–2007.

Kim EK, Choi E-J. Compromised MAPK signaling in human diseases: an update. Arch Toxicol. 2015;89(6):867–82.

Zhang C, Wu Q, Huang H, Chen X, Huang T, Li W, et al. Caveolin-1 promotes Rfng expression via Erk-Jnk-p38 signaling pathway in mouse hepatocarcinoma cells. J Physiol Biochem. 2019;75(4):549–59.

Hoang VT, Nyswaner K, Torres-Ayuso P, Brognard J. The protein kinase MAP3K19 phosphorylates MAP2Ks and thereby activates ERK and JNK kinases and increases viability of KRAS-mutant lung cancer cells. J Biol Chem. 2020;295(25):8470–9.

Xue C, Wang K, Jiang X, Gu C, Yu G, Zhong Y, et al. The down-regulation of SUZ12 accelerates the migration and invasion of liver cancer cells via activating ERK1/2 pathway. J Cancer. 2019;10(6):1375–84.

Wang L, Han L, Tao Z, Zhu Z, Han L, Yang Z, et al. The curcumin derivative WZ35 activates ROS-dependent JNK to suppress hepatocellular carcinoma metastasis. Food Funct. 2018;9(5):2970–8.

Wan LCK, Maisonneuve P, Szilard RK, Lambert J-P, Ng TF, Manczyk N, et al. Proteomic analysis of the human KEOPS complex identifies C14ORF142 as a core subunit homologous to yeast Gon7. Nucleic Acids Res. 2017;45(2):805–17.

Wu P-K, Hong S-K, Veeranki S, Karkhanis M, Starenki D, Plaza JA, et al. A mortalin/HSPA9-mediated switch in tumor-suppressive signaling of Raf/MEK/extracellular signal-regulated kinase. Mol Cell Biol. 2013;33(20):4051–67.

Shukla AK, Pragya P, Chaouhan HS, Tiwari AK, Patel DK, Abdin MZ, et al. Heat shock protein-70 (Hsp-70) suppresses paraquat-induced neurodegeneration by inhibiting JNK and caspase-3 activation in Drosophila model of Parkinson’s disease. PLoS ONE. 2014;9(6):e98886.

Mooney EC, Sahingur SE. The ubiquitin system and A20: implications in health and disease. J Dent Res. 2021;100(1):10–20.

Feng X, Jia Y, Zhang Y, Ma F, Zhu Y, Hong X, et al. Ubiquitination of UVRAG by SMURF1 promotes autophagosome maturation and inhibits hepatocellular carcinoma growth. Autophagy. 2019;15(7):1130–49.

Lin X, Li A-M, Li Y-H, Luo R-C, Zou Y-J, Liu Y-Y, et al. Silencing MYH9 blocks HBx-induced GSK3β ubiquitination and degradation to inhibit tumor stemness in hepatocellular carcinoma. Signal Transduct Target Ther. 2020;5(1):13.

Jiang X, Wang G, Liu Y, Mei C, Yao Y, Wu X, et al. A novel long non-coding RNA RP11–286H15.1 represses hepatocellular carcinoma progression by promoting ubiquitination of PABPC4. Cancer Lett. 2021;499:109–21.

Al-Khadairi G, Decock J. Cancer testis antigens and immunotherapy: where do we stand in the targeting of PRAME? Cancers (Basel). 2019;11(7):984.

Costessi A, Mahrour N, Sharma V, Stunnenberg R, Stoel MA, Tijchon E, et al. The human EKC/KEOPS complex is recruited to Cullin2 ubiquitin ligases by the human tumour antigen PRAME. PLoS ONE. 2012;7(8):e42822.

Costessi A, Mahrour N, Tijchon E, Stunnenberg R, Stoel MA, Jansen PW, et al. The tumour antigen PRAME is a subunit of a Cul2 ubiquitin ligase and associates with active NFY promoters. EMBO J. 2011;30(18):3786–98.

Thông tin
Thông tin xuất bản

Springer Science and Business Media LLC

Tập 26 Số 1

Thông tin tác giả